CA2263826A1 - Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob - Google Patents
Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob Download PDFInfo
- Publication number
- CA2263826A1 CA2263826A1 CA002263826A CA2263826A CA2263826A1 CA 2263826 A1 CA2263826 A1 CA 2263826A1 CA 002263826 A CA002263826 A CA 002263826A CA 2263826 A CA2263826 A CA 2263826A CA 2263826 A1 CA2263826 A1 CA 2263826A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- analog
- amino acids
- amino acid
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des méthodes pour accroître la sensibilité du récepteur de la protéine OB fonctionnelle et ses utilisations.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70598196A | 1996-08-30 | 1996-08-30 | |
| US08/705,981 | 1996-08-30 | ||
| PCT/US1997/015086 WO1998008512A1 (fr) | 1996-08-30 | 1997-08-26 | Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2263826A1 true CA2263826A1 (fr) | 1998-03-05 |
Family
ID=24835722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002263826A Abandoned CA2263826A1 (fr) | 1996-08-30 | 1997-08-26 | Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1001768A1 (fr) |
| JP (1) | JP2001501177A (fr) |
| AU (1) | AU4237797A (fr) |
| CA (1) | CA2263826A1 (fr) |
| WO (1) | WO1998008512A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| AU2002236641B2 (en) * | 2000-12-01 | 2006-08-03 | Battelle Memorial Institute | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
| WO2002043750A2 (fr) * | 2000-12-01 | 2002-06-06 | Battelle Memorial Institute | Procede de stabilisation de biomolecules dans des formulations liquides |
| PT2219031E (pt) | 2001-10-22 | 2013-05-17 | Amgen Inc | Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| EP2286838A3 (fr) | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Traitement de l'obésité et de maladies liés à l'obésité |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| CA2813038C (fr) | 2010-09-28 | 2021-12-28 | Amylin Pharmaceuticals, Llc | Leptines hautement solubles |
| HUE040496T2 (hu) | 2012-09-27 | 2019-03-28 | Childrens Medical Ct Corp | Vegyületek elhízás kezelésére és alkalmazási eljárásaik |
| RS58422B1 (sr) | 2013-11-26 | 2019-04-30 | Childrens Medical Ct Corp | Jedinjenja za tretiranje gojaznosti i postupci za njihovu upotrebu |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| FI3509624T3 (fi) | 2016-09-12 | 2023-10-18 | Amryt Pharmaceuticals Inc | Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| WO1997016189A1 (fr) * | 1995-11-01 | 1997-05-09 | Merck & Co., Inc. | Traitement combine du diabete et de l'obesite |
-
1997
- 1997-08-26 AU AU42377/97A patent/AU4237797A/en not_active Abandoned
- 1997-08-26 WO PCT/US1997/015086 patent/WO1998008512A1/fr not_active Application Discontinuation
- 1997-08-26 EP EP97940645A patent/EP1001768A1/fr not_active Withdrawn
- 1997-08-26 CA CA002263826A patent/CA2263826A1/fr not_active Abandoned
- 1997-08-26 JP JP10511882A patent/JP2001501177A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001501177A (ja) | 2001-01-30 |
| EP1001768A1 (fr) | 2000-05-24 |
| AU4237797A (en) | 1998-03-19 |
| WO1998008512A1 (fr) | 1998-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8080254B2 (en) | OB fusion protein compositions and methods | |
| EP0954588B1 (fr) | Procedes et compositions comprenant une proteine de fusion ob | |
| EP0866720B1 (fr) | Proteine ob pour augmenter la masse tissulaire maigre | |
| EP0865294B1 (fr) | Procedes pour diminuer ou maintenir un niveau bas de lipides dans le sang, en utilisant des compositions de proteine ob | |
| US7718400B2 (en) | Methods of increasing lean tissue mass using OB protein compositions | |
| CA2263826A1 (fr) | Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob | |
| WO1997038014A1 (fr) | Compositions pharmaceutiques renfermant la fibuline et procedes connexes | |
| AU2006201747B2 (en) | Methods of Increasing Lean Tissue Mass Using OB Protein Compositions | |
| AU2004200516B2 (en) | Methods of Increasing Lean Tissue Mass Using OB Protein Compositions | |
| AU4258200A (en) | Method for increasing sensitivity of an individual to Ob protein by upregulating Ob protein receptor | |
| AU2003201360B2 (en) | Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions | |
| MXPA99001875A (en) | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor | |
| AU2004202448A1 (en) | OB Fusion Protein Compositions and Methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |